Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096083 · ClinicalTrials.gov registry record · Phase 2
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
A Phase 2 study, sponsored by Delcath Systems.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00096083 is a Phase 2 study that has completed, run by Delcath Systems. The registered enrollment target is 56 participants.
The verdict
NCT00096083, a Phase 2 study, has completed, sponsored by Delcath Systems.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving an hepatic arterial infusion of melphalan together with hepatic perfusion works in treating patients with unresectable liver cancer.
Interventions
- DRUG melphalan
- DRUG isolated perfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096083
The ClinicalTrials.gov registry entry for NCT00096083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delcath Systems, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00096083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096083 about?
NCT00096083 is a clinical study titled "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer". RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells...
What is the current status of trial NCT00096083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2004-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00096083?
The interventions under investigation include: melphalan (DRUG), isolated perfusion (DRUG).
Who is sponsoring clinical trial NCT00096083?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.